March 18th 2023
A recent study indicated that lebrikizumab treatment for 16 weeks was effective for adolescents and adults with moderate-to-severe atopic dermatitis.
Establishing accurate case definitions for childhood respiratory and skin conditions
February 17th 2023A research letter addresses the challenges of accurately diagnosing asthma, atopic eczema, and allergic rhinitis in children under 5 years old and the use of Read codes and prescription data as diagnostic criteria.
Arcutis submits roflumilast cream for treating plaque psoriasis in patients aged 2 to 11 years
December 19th 2022Arcutis Biotherapeutics, Inc has submitted a supplemental New Drug Application for roflumilast cream (ZORYVE) to the US Food and Drug Administration for treatment of plaque psoriasis in children aged 2 to 11 years.
Roflumilast cream safe, effective for atopic dermatitis in children 6 years and up
November 16th 2022Recently announced data from the INTEGUMENT-1 phase 3 clinical trial demonstrated positive safety and efficacy results for atopic dermatitis patients 6 years and older treated with roflumilast cream (Arcutis Biotherapeutics).
Frequent allergies in pediatric atopic dermatitis, eosinophilic esophagitis patients in Puerto Rico
November 16th 2022New data presented at ACAAI 2022 observed various trends in allergies associated with eczema and eosinophilic esophagitis, comparing observed data with that of patients in the United States.
Pediatric patients with AD have an increased risk of type 2 inflammatory diseases
July 13th 2022A better understanding of this atopic diathesis and the atopic march often seen in pediatric patients is necessary to optimally treat and manage the patient population, ideally in a multidisciplinary setting.